Approximately 18% of the patients with high-grade serous ovarian carcinoma present somatic amplification of BRD4 [4, 10], which is often associated with increased BRD4 gene and protein expression [10, 11, 64]. Here, BRD4 is linked to ovarian serous carcinoma.